The present invention generally relates to devices and methods for the repair of inter-vertebral discs. More, specifically, the present invention relates to devices and methods for the treatment of spinal disorders associated with the nucleus, annulus and inter-vertebral disc.
Inter-vertebral disc disease is a major worldwide health problem. In the United States alone almost 700,000 spine procedures are performed each year and the total cost of treatment of back pain exceeds $30 billion. Age related changes in the disc include diminished water content in the nucleus and increased collagen content by the 4th decade of life. Loss of water binding by the nucleus results in more compressive loading of the annulus. This renders the annulus more susceptible to delamination and damage. Damage to the annulus, in turn, accelerates disc degeneration and degeneration of surrounding tissues such as the facet joints.
The two most common spinal surgical procedures performed are discectomy and spinal fusion. These procedures only address the symptom of lower back pain. Both procedures actually worsen the overall condition of the affected disc and the adjacent discs. A better solution would be implantation of an artificial disc for treatment of the lower back pain and to restore the normal anatomy and function of the diseased disc.
The concept of a disc prosthesis dates back to a French patent by van Steenbrugghe in 1956. 17 years later, Urbaniak reported the first disc prosthesis implanted in animals. Since this time, numerous prior art devices for disc replacement have been proposed and tested. These are generally divided into devices for artificial total disc replacement or artificial nucleus replacement. The devices proposed for artificial total disc replacement, such as those developed by Kostuik, that generally involve some flexible central component attached to metallic endplates which may be affixed to the adjacent vertebrae. The flexible component may be in the form of a spring or alternatively a polyethylene core (Marnay). The most widely implanted total artificial disc to date is the Link SB Charite disc which is composed of a biconvex ultra high molecular weight polyethylene spacer interfaced with two endplates made of cobalt-chromium-molybdenum alloy. Over 2000 of these have been implanted with good results. However device failure has been reported along with dislocation and migration. The Charite disc also requires an extensive surgical dissection via an anterior approach.
The approach of artificial nucleus replacement has several obvious advantages over artificial total disc replacement. By replacing only the nucleus, it preserves the remaining disc structures such as the annulus and endplates and preserves their function. Because the annulus and endplates are left intact, the surgical procedure is much simpler and operative time is less. Several nuclear prostheses can be placed via a minimally invasive endoscopic approach. The nucleus implant in widest use today is the one developed by Raymedica (Bloomington, Minn.) which consists of a hydrogel core constrained in a woven polyethylene jacket. The pellet shaped hydrogel core is compressed and dehydrated to minimize size prior to placement. Upon implantation the hydrogel begins to absorb fluid and expand. The flexible but inelastic jacket permits the hydrogel to deform and reform in response to compressive forces yet constrain the horizontal and vertical expansion (see U.S. Pat. Nos. 4,904,260 and 4,772,287 to Ray). Other types of nuclear replacement have been described which include either an expansive hydrogel or polymer to provide for disc separation and relieve compressive load on the other disc components (see U.S. Pat. No. 5,192,326 to Boa). Major limitations of nuclear prostheses are that they can only be used in patients in whom disc degeneration is at an early stage because they require the presence of a competent natural annulus. In discs at later stages of degeneration the annulus is often torn, flattened and/or delaminated and may not be strong enough to provide the needed constraint. Additionally, placement of the artificial nucleus often requires access through the annulus. This leaves behind a defect in the annulus through which the artificial nucleus may eventually extrude compressing adjacent structures. What is clearly needed is a replacement or reinforcement for the natural annulus which may be used in conjunction with these various nuclear replacement devices.
Several annular repair or reinforcement devices have been previously described. These include the annulus reinforcing band described by U.S. Pat. No. 6,712,853 to Kuslich, which describes an expansile band pressurized with bone graft material or like, expanding the band. U.S. Pat. No. 6,883,520B2 to Lambrecht et al, describes a device and method for constraining a disc herniation utilizing an anchor and membrane to close the annular defect. U.S. patent application Ser. No. 10/676,868 to Slivka et al. describes a spinal disc defect repair method. U.S. Pat. No. 6,806,595 B2 to Keith et al. describes disc reinforcement by implantation of reinforcement members around the annulus of the disc. U.S. Pat. No. 6,592,625 B2 to Cauthen describes a collapsible patch put through an aperture in the subannular space. U.S. patent application Ser. No. 10/873,899 to Milbocker et al. describes injection of in situ polymerizing fluid for repair of a weakened annulus fibrosis or replacement or augmentation of the disc nucleus.
Each of these prior art references describes devices or methods utilized for repair of at least a portion of the diseased annulus. What is clearly needed is an improved spinal disc device and method capable of reinforcing the entire annulus circumferentially. In addition what is clearly needed is a spinal disc device and method which may be easily placed into the inter-vertebral space and made to conform to this space. The need for an improved spinal disc device and method capable of reinforcing the entire annulus that may be utilized either in conjunction with an artificial nucleus pulposis or may be used as a reinforcement for the annulus fibrosis and as an artificial nucleus pulposis is evident.
The present invention addresses these needs by providing improved spinal disc device and methods for the treatment of inter-vertebral disc disease. The improved device and methods of the present invention specifically address disc related pain but may have other significant applications not specifically mentioned herein. For purposes of illustration only, and without limitation, the present invention is discussed in detail with reference to the treatment of damaged discs of the adult human spinal column.
As will become apparent from the following detailed description, the improved spinal disc device and methods of the present invention may reduce if not eliminate back pain while maintaining near normal anatomical motion. The present invention relates to devices and methods which may be used to reinforce or replace the native annulus, replace the native nucleus, replace both the annulus and nucleus or facilitate fusion of adjacent vertebrae. The devices of the present invention are particularly well suited for minimally invasive methods of implantation.
The spinal disc device is a catheter based device with a unique delivery system which is placed into the intervertebral space following discectomy performed by either traditional surgical or endoscopic approaches. The distal end of the catheter is comprised of an expandable loop or mesh that is removably attached to a delivery tubular member using a screw threaded section. Coaxially within the delivery tubular member is an injection tubular member, an introducer tubular member and a guiding member. The expandable loop or mesh may be increased in diameter by advancement of the introducer tubular member and/or the injection tubular member. The expandable loop or mesh may be formed of a woven, knitted, embroidered or braided material and may be made of PEEK (polyetheretherketone), Nylon, Dacron, synthetic polyamide, polypropylene, polyolefin (e.g. heat shrink tubing), Teflon (PTFE), polyurethane, Pebax, Hytrel, expanded polytetrafluroethylene (e-PTFE), polyethylene and ultra-high molecular weight fibers of polyethylene (UHMWPE) commercially available as Spectra™ or Dyneema™, as well as other high tensile strength materials such as Vectran™, Kevlar™, natural or artificially produced silk and commercially available suture materials used in a variety of surgical procedures. Alternatively the expansile loop or mesh portion of the catheter may be made of a biodegradable or bioabsorbable material such as resorbable collagen, LPLA (poly(l-lactide)), DLPLA (poly(dl-lactide)), LPLA-DLPLA, PGA (polyglycolide), PGA-LPIA or PGA-DLPLA, polylactic acid and polyglycolic acid which is broken down and bioabsorbed by the patient over a period of time. Alternatively the expansile portion of the catheter may be formed from metallic materials, for example, stainless steel, Elgiloy™, Nitinol, or other biocompatible metals. Further, it is anticipated that the expansile loop portion of the device could be made from a flattened tubular knit, weave, mesh or foam structure.
The expandable loop or mesh is formed such that one end of the loop feeds into its other end (overlapping), similar to a snake eating its own tail forming the shape of a toroid with an inner chamber and a central open area. The overlapping section of the expandable mesh has a threaded nut section which engages the screw threads of the delivery tubular member and provides for the introducer tubular member, the injection tubular member, and the guiding member to have access to the inner chamber of the expandable mesh.
Once one or more materials are delivered or injected into the inner chamber, the expandable loop or mesh can be detached from the deliver components (delivery tubular member, introducer deliver member, injection tubular member, and guiding member) by unscrewing the delivery tubular member from the threaded nut section of the expandable loop or mesh. Due to the design that one end of the loop feeds into its other end (overlapping), once the delivery tubular member is detached, the thread net section with access to the inner chamber will become self-closes.
The present invention consists of a device and method, whereby the present invention is first delivered and expanded within the inter-vertebral space to the limits of the inner portion of the native annulus to artificially replace all or a portion of a damaged nucleus.
The present invention consists of a device and method, whereby the invention is first delivered and expanded within the inter-vertebral space to the limits of the inner portion of the native annulus and then an injection of polymeric or hydrogel or like material is conducted to reinforce or artificially replace the native annulus.
The present invention also consists of a device and method, whereby the invention is first delivered within the inter-vertebral space and into the area of the nucleus, which may have been previously removed, and expanded to the limits of the outer portion of the area of the native nucleus and then injected with a polymer or hydrogel or like material conducted to reinforce or artificially replace the native nucleus.
The present invention also consists of a device and method, whereby the invention is first delivered within the inter-vertebral space and expanded within the inter-vertebral space to the limits of the outer portion of the native annulus and then an injection of polymeric or hydrogel material is conducted to reinforce or artificially replace the native annulus. Then the present invention is delivered into the nucleus area and expanded to the limits of the outer portion of the native nucleus or an artificial nucleus concurrently placed and then an injection of polymeric or hydrogel material is conducted to reinforce or artificially replace or reinforce the nucleus.
The present invention and variations of its embodiments is summarized herein. Additional details of the present invention and embodiments of the present invention may be found in the Detailed Description of the Preferred Embodiments and Claims below. These and other features, aspects and advantages of the present invention will become better understood with reference to the following descriptions and claims.
Near the distal end of the elongated catheter, is situated an expandable, braided, woven, knitted or embroidered substantially tubular loop 150 in an unfilled (pre-delivery or pre-injection of one or more materials) configuration. The distal end of one end of the expandable mesh or loop is fed into the proximal end, of the other end of the expandable mesh or loop in a manner similar to a snake eating its own tail (with overlapping section). This design results in an expandable mesh 150 having a toroidal configuration with an inner chamber 168 and inside open central area 182. Also this design results in an overlapping section 170 whereby a screw thread attachment means 172a and 172b are designed to removable engage the delivery tube member 152 (shown in more detail in
The expandable mesh 150 is fabricated as a knit, weave or braid and can be constructed from non-degradable materials. Suitable non-degradable materials for the expansile loop 150, include, but are not limited to, polyetheretherketone (PEEK), Nylon, Dacron, synthetic polyamide, polypropylene, expanded polytetrafluroethylene (e-PTFE), polyethylene, polyolefin (e.g. heat shrink tubing, Teflon (PTFE), polyurethane, Pebax, Hytrel, and ultra-high molecular weight fibers of polyethylene (UHMWPE) commercially available as Spectra™ or Dyneema™, as well as other high tensile strength materials such as Vectran™, Kevlar™, natural or artificially produced silk and commercially available suture materials used in a variety of surgical procedures. The expandable mesh 150 is fabricated as a weave knit or braid and can be constructed from biodegradable or bioabsorbable materials. Suitable biodegradable and bioabsorbable materials for the expandable mesh 150 include, but are not limited to, resorbable collagen, LPLA (poly(l-lactide)), DLPLA (poly(dl-lactide)), LPLA-DLPLA, PGA (polyglycolide), PGA-LPLA or PGA-DLPLA, and biodegradable sutures made from polylactic acid, polyglycolic acid, and polycaprol acetone.
In addition, for some embodiments, suitable metallic materials for the expansile loop 150 may be used that include, but are not limited to, stainless steel, cobalt-chrome alloy, titanium, titanium alloy, or nickel-titanium shape memory alloys, among others. It is further contemplated that the metallic mesh can be interwoven with non-resorbable polymers such as nylon fibers, polypropylene fibers, carbon fibers and polyethylene fibers, among others, to form a metal-polymer composite weave. Further examples of suitable non-resorbable materials include DACRON and GORE-TEX. One feature of the expandable mesh or loop 150 is that it needs to have pore sizes or openings that are small enough to hold the filling material or nucleus from extruding out and large enough to maintain flexibility and expansion characteristics.
Shown in
Shown in
Shown in
Shown
Shown in
In the other embodiment (shown in
In typical clinical use, the nucleus of the damaged disc has been previously removed by discectomy techniques either through an anterior, posterior, posterolateral or lateral surgical approach. The expandable mesh 150 in a compressed configuration within an outer catheter element or sheath and is advanced through an access tube or cannula previously placed into the inter-vertebral space. This cannula may access the inter-vertebral space from a lateral, posterior, posterolateral or anterior approach that is well known to physicians skilled in the art. The expandable mesh is then advanced into the inter-vertebral space through the access tube. As shown in
Once the expandable mesh 150 is delivered into the inter-vertebral space, the collet tubular member 151 is partially proximately located as shown in
As shown in
In addition to the materials disclosed, additional suitable fluid materials for nucleus replacement include, but are not limited to, various pharmaceuticals (steroids, antibiotics, tissue necrosis factor alpha or its antagonists, analgesics); growth factors, genes or gene vectors in solution; biologic materials (hyaluronic acid, non-crosslinked collagen, fibrin, liquid fat or oils); synthetic polymers (polyethylene glycol, liquid silicones, synthetic oils); and saline.
Additional materials for the embodiments of the present invention 145 to be delivered into the expandable mesh 150 include certain biocompatible cement and plaster of Paris materials. Cement products employ a binding agent to hold silicone materials or sand and other aggregates together in a hard, stone like mass. Other chemicals can be added to the cement components to affect the curing time and final plasticity of the cement product. Plaster of Paris biomaterials are formed from calcium sulfate and are ideal materials for molding, casting and making various forms. The hardness of the plaster of Paris biomaterials can attain a relatively high hardness (Shore A Hardness of 65+/−5) and can fully harden in 30 minutes of less. Both the biocompatible cement and plaster of Paris materials are desirable candidate materials to be used to deliver and fill within the expansile loop or center hole of the present invention for the fusing two adjacent vertebrae together.
Example of calcium phosphate-based bone substitutes having the necessary characteristics consist of calcium phosphate being a substantially monolithic tetracalcium phosphate (CA4(PO4)2O). The calcium phosphate may further comprise surface protrusions of calcium phosphate to enhance bone integration. Alternatively, the suitable calcium phosphate-based bone substitute can comprise minor amounts of additional substances, such as Na3PO4; Na2HPO4; NaH2PO4; Na4HPO4.7H2O; Na3PO4.12H2O; H3PO4; CaSO4; (NH4)3PO4; (NH4)2HPO4; (NH4)H2PO4; (NH4)3PO4.3H2O; NaHCO3; CaCO3; Na2CO3; KH2PO4; K2HPO4; K3PO4; CaF2:SrF2; Na2SiF6; Na2PO3F, and the like. The suitable bone substitute can also comprise an amount of one or more active agents suitable to promote bone growth, such as a growth factor, a bone morphology protein, or a pharmaceutical carrier there for. In addition, the expandable mesh 150 can include materials that will act as a scaffold or carrier for delivering biologic medicaments to vertebral tissues. The expansile mesh can be previously treated (for example, by soaking) with certain biologics (e.g. BMP, OP-1), or the access tube can be constructed to include a biologic delivery means such that the biologic is 1) delivered while the injected material 180 is being deployed, 2) delivered prior to deploying the injected material 180, 3) delivery subsequent to deploying the injected material 180, or any combinations thereof.
Furthermore, the present invention expandable mesh 150 can be coated or integrated with an osteogenic paste composition including a paste-form carrier such as a gelatin paste and at least one osteogenic factor such as BMP-2 or another similar bone morphogenetic protein. The inclusion of osteoblast and osteoclast-stimulating osteogenic factors in a paste-form composition including a resorbable paste carrier causes a rapid and premature resorption of the carrier. This rapid resorption of the carrier can diminish or eliminate the capacity of the paste-form composition to effectively stimulate and support new bone formation in a void filled with the composition. This is particularly the case in humans in which the rate of new bone formation is relatively slow.
Other suitable materials to induce bone fusion including, but are not limited to, bond graft materials such as any described “bone cements” or any polymeric bone graft compounds, bone chips, bone graft materials, nylon fibers, carbon fibers, glass fibers, collagen fibers, ceramic fibers, polyethylene fibers, polypropylene fibers, poly(ethylene terephthalate), polyglycolides, polylactides, and combinations thereof, or a biomaterial or any suitable material (as described above), as the present invention is not limited in this respect.
In addition, suitable materials that can be placed directed into the expandable mesh 150 and allowed to expand through the absorption of liquids such as water include, but are not limited to, swelling hydrogel materials (e.g. polyacrliamide, polyacrylonitrile, polyvinyl alcohol or other biocompatible hydrogels). Examples of suitable materials for solid or semi-solid members include solid fibrous collagen or other suitable hard hydrophilic biocompatible material. The swelling of these materials may result in further expansion of the expansile braided, woven or embroidered loop and an increase in the inter-vertebral disc height.
In some cases, a multiphase system may be employed, for example, a combination of solids, fluids or gels may be used. Such materials may create primary and secondary levels of flexibility within the braided, woven embroidered expansile loop and within the inter-vertebral disc space.
For example, the hydrogel materials (e.g. polyacrliamide, polyacrylonitrile, polyvinyl alcohol or other biocompatible hydrogels or combinations can be dissolved in a solvent, such as dimethylsulfoxide, analogues/homologues of dimethylsulfoxide, ethanol, ethyl lactate, acetone, glycerin or combinations thereof. Small amounts of water could also be added to the solvent/hydrogel combination to adjust the solutions viscosity. This solvent/hydrogel combination can be injected into the inter-vertebral space to replace the nucleus, the annulus, or both the nucleus and annulus. The expandable mesh 150 will assist in containing and supporting the solvent/hydrogel combination. After delivery, the solvent is replaced by bodily fluids and the hydrogel precipitates out of solution into a hydrated solid. The solvent is adsorbed into the body tissues. Introducing an aqueous solvent, such as water or saline, into the inter-vertebral space containing the solvent/hydrogel combination can be performed to increase the precipitation speed of the hydrogel. This second step facilitates the precipitation or solidification of the hydrogel material which swells and fills the desired inter-vertebral space. As shown in
Once the expandable mesh 150 is substantially filled with an injectable material 180, as shown in
It should be understood that the foregoing description of the present invention is intended merely to be illustrative thereof and that other embodiments, modifications, and equivalents of the invention are within the scope of the invention recited in the claims appended hereto. Further, although each embodiment described above includes certain features, the invention is not limited in this respect. Thus, one or more of the above-described or other features of the invention, method of delivery, or injection of biomaterial may be employed singularly or in any suitable combination, as the present invention is not limited to a specific embodiment.
The present application is a continuation-in-part of patent application Ser. No. 11/153,776 filed on Jun. 15, 2005, Ser. No. 11/272,299 filed on Nov. 10, 2005, Ser. No. 11/359,335 filed on Feb. 22, 2006 now U.S. Pat. No. 7,547,319 and Ser. No. 11/700,509 filed on Jan. 31, 2007. These applications are incorporated herein by this reference.
Number | Name | Date | Kind |
---|---|---|---|
3875595 | Froning | Apr 1975 | A |
4772287 | Ray et al. | Sep 1988 | A |
5108404 | Scholten et al. | Apr 1992 | A |
5171280 | Baumgartner | Dec 1992 | A |
5549679 | Kuslich | Aug 1996 | A |
5571189 | Kuslich | Nov 1996 | A |
5718702 | Edwards | Feb 1998 | A |
5730127 | Avitall | Mar 1998 | A |
5785705 | Baker | Jul 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5863291 | Schaer | Jan 1999 | A |
5879295 | Li et al. | Mar 1999 | A |
6071274 | Thompson et al. | Jun 2000 | A |
6183518 | Ross et al. | Feb 2001 | B1 |
6235043 | Reiley et al. | May 2001 | B1 |
6248131 | Felt et al. | Jun 2001 | B1 |
6264659 | Ross et al. | Jul 2001 | B1 |
6332880 | Yang et al. | Dec 2001 | B1 |
6375659 | Erbe et al. | Apr 2002 | B1 |
6395034 | Suddaby | May 2002 | B1 |
6428576 | Haldimann | Aug 2002 | B1 |
6436143 | Ross et al. | Aug 2002 | B1 |
6464700 | Koblish et al. | Oct 2002 | B1 |
6508839 | Lambrecht et al. | Jan 2003 | B1 |
6533817 | Norton et al. | Mar 2003 | B1 |
6582467 | Teitelbaum et al. | Jun 2003 | B1 |
6607505 | Thompson et al. | Aug 2003 | B1 |
6613046 | Jenkins et al. | Sep 2003 | B1 |
6620196 | Trieu | Sep 2003 | B1 |
6733496 | Sharkey et al. | May 2004 | B2 |
6733531 | Trieu | May 2004 | B1 |
6733533 | Lozier | May 2004 | B1 |
6764514 | Li et al. | Jul 2004 | B1 |
6783546 | Zucherman et al. | Aug 2004 | B2 |
6878155 | Sharkey et al. | Apr 2005 | B2 |
6893466 | Trieu | May 2005 | B2 |
6899719 | Reiley et al. | May 2005 | B2 |
6916306 | Jenkins et al. | Jul 2005 | B1 |
6932843 | Smith et al. | Aug 2005 | B2 |
6969404 | Ferree | Nov 2005 | B2 |
6976979 | Lawrence et al. | Dec 2005 | B2 |
6979341 | Scribner et al. | Dec 2005 | B2 |
7001431 | Bao et al. | Feb 2006 | B2 |
7004970 | Cauthen, III et al. | Feb 2006 | B2 |
7008401 | Thompson et al. | Mar 2006 | B2 |
7029471 | Thompson et al. | Apr 2006 | B2 |
7044954 | Reiley et al. | May 2006 | B2 |
7066960 | Dickman | Jun 2006 | B1 |
7077865 | Bao et al. | Jul 2006 | B2 |
7175619 | Koblish et al. | Feb 2007 | B2 |
7267692 | Fortin et al. | Sep 2007 | B2 |
7306610 | Chern Lin et al. | Dec 2007 | B2 |
7318840 | McKay | Jan 2008 | B2 |
7322962 | Forrest | Jan 2008 | B2 |
7427295 | Ellman et al. | Sep 2008 | B2 |
7442210 | Segal et al. | Oct 2008 | B2 |
7465318 | Sennett et al. | Dec 2008 | B2 |
7507243 | Lambrecht et al. | Mar 2009 | B2 |
7520888 | Trieu | Apr 2009 | B2 |
7534268 | Hudgins et al. | May 2009 | B2 |
7544196 | Bagga et al. | Jun 2009 | B2 |
7547319 | Segal et al. | Jun 2009 | B2 |
7547326 | Bhatnagar et al. | Jun 2009 | B2 |
7553307 | Bleich et al. | Jun 2009 | B2 |
7575577 | Boyd et al. | Aug 2009 | B2 |
7597714 | Suddaby | Oct 2009 | B2 |
7601157 | Boyd et al. | Oct 2009 | B2 |
7601172 | Segal et al. | Oct 2009 | B2 |
7618457 | Hudgins | Nov 2009 | B2 |
7618461 | Trieu | Nov 2009 | B2 |
7632294 | Milbodker et al. | Dec 2009 | B2 |
7645301 | Hudgins et al. | Jan 2010 | B2 |
7699894 | O'Neil et al. | Apr 2010 | B2 |
7713301 | Bao et al. | May 2010 | B2 |
7717918 | Truckai et al. | May 2010 | B2 |
7717956 | Lang | May 2010 | B2 |
7717958 | Cragg et al. | May 2010 | B2 |
7731681 | Schaer et al. | Jun 2010 | B2 |
7758647 | Arnin et al. | Jul 2010 | B2 |
7780734 | Johnson et al. | Aug 2010 | B2 |
7785368 | Schaller | Aug 2010 | B2 |
7789912 | Manzi et al. | Sep 2010 | B2 |
7799056 | Sankaran | Sep 2010 | B2 |
7799078 | Embry et al. | Sep 2010 | B2 |
7799833 | Boyd | Sep 2010 | B2 |
7824444 | Biscup et al. | Nov 2010 | B2 |
7837733 | Collins et al. | Nov 2010 | B2 |
7842040 | Rabiner et al. | Nov 2010 | B2 |
7842095 | Klein | Nov 2010 | B2 |
7857808 | Oral et al. | Dec 2010 | B2 |
7867278 | Lambrecht et al. | Jan 2011 | B2 |
7883511 | Fernyhough | Feb 2011 | B2 |
7887593 | McKay et al. | Feb 2011 | B2 |
7901460 | Sherman | Mar 2011 | B2 |
7905863 | Forrest | Mar 2011 | B1 |
7914537 | Boyd et al. | Mar 2011 | B2 |
7914538 | Howe | Mar 2011 | B2 |
20020026195 | Layne et al. | Feb 2002 | A1 |
20020049449 | Bhatnagar et al. | Apr 2002 | A1 |
20020077701 | Kuslich | Jun 2002 | A1 |
20020147496 | Belef et al. | Oct 2002 | A1 |
20020147497 | Belef et al. | Oct 2002 | A1 |
20020173851 | McKay | Nov 2002 | A1 |
20030088249 | Furderer | May 2003 | A1 |
20030195628 | Bao et al. | Oct 2003 | A1 |
20040054413 | Higham et al. | Mar 2004 | A1 |
20040059417 | Smith et al. | Mar 2004 | A1 |
20040068268 | Boyd et al. | Apr 2004 | A1 |
20040106999 | Mathews | Jun 2004 | A1 |
20040127992 | Serhan et al. | Jul 2004 | A1 |
20040143333 | Bain et al. | Jul 2004 | A1 |
20040167625 | Beyar et al. | Aug 2004 | A1 |
20040186471 | Trieu | Sep 2004 | A1 |
20040215344 | Hochschuler et al. | Oct 2004 | A1 |
20040230309 | DiMauro et al. | Nov 2004 | A1 |
20040260397 | Lambrecht et al. | Dec 2004 | A1 |
20040267368 | Kuslich | Dec 2004 | A1 |
20050004515 | Hart et al. | Jan 2005 | A1 |
20050010297 | Watson et al. | Jan 2005 | A1 |
20050015150 | Lee | Jan 2005 | A1 |
20050038514 | Helm et al. | Feb 2005 | A1 |
20050049592 | Keith et al. | Mar 2005 | A1 |
20050049604 | Singer et al. | Mar 2005 | A1 |
20050065609 | Wardlaw | Mar 2005 | A1 |
20050090901 | Studer | Apr 2005 | A1 |
20050113923 | Acker et al. | May 2005 | A1 |
20050154463 | Trieu | Jul 2005 | A1 |
20050182418 | Boyd et al. | Aug 2005 | A1 |
20050209557 | Carroll et al. | Sep 2005 | A1 |
20050209595 | Karmon | Sep 2005 | A1 |
20050234498 | Gronemeyer et al. | Oct 2005 | A1 |
20050245938 | Kochan | Nov 2005 | A1 |
20050251259 | Suddaby | Nov 2005 | A1 |
20050278027 | Hyde, Jr. | Dec 2005 | A1 |
20050283246 | Cauthen et al. | Dec 2005 | A1 |
20060052874 | Johnson et al. | Mar 2006 | A1 |
20060084983 | Kim | Apr 2006 | A1 |
20060084988 | Kim | Apr 2006 | A1 |
20060085069 | Kim | Apr 2006 | A1 |
20060106461 | Embry et al. | May 2006 | A1 |
20060116767 | Magerl et al. | Jun 2006 | A1 |
20060122704 | Vresilovic et al. | Jun 2006 | A1 |
20060149279 | Mathews | Jul 2006 | A1 |
20060149379 | Kuslich et al. | Jul 2006 | A1 |
20060149380 | Lotz et al. | Jul 2006 | A1 |
20060173545 | Cauthen et al. | Aug 2006 | A1 |
20060195115 | Ferree | Aug 2006 | A1 |
20060235523 | Gil | Oct 2006 | A1 |
20060247780 | Bert | Nov 2006 | A1 |
20060253198 | Myint et al. | Nov 2006 | A1 |
20060255503 | Higham et al. | Nov 2006 | A1 |
20060287726 | Segal et al. | Dec 2006 | A1 |
20070055265 | Schaller | Mar 2007 | A1 |
20070055272 | Schaller | Mar 2007 | A1 |
20070093899 | Dutoit et al. | Apr 2007 | A1 |
20070173943 | Dulak et al. | Jul 2007 | A1 |
20070233222 | Roeder et al. | Oct 2007 | A1 |
20080051800 | Diaz et al. | Feb 2008 | A1 |
20080091199 | Cragg | Apr 2008 | A1 |
20080103505 | Fransen | May 2008 | A1 |
20080132899 | Shadduck et al. | Jun 2008 | A1 |
20080132934 | Reiley et al. | Jun 2008 | A1 |
20080133012 | McGuckin | Jun 2008 | A1 |
20080140084 | Osorio et al. | Jun 2008 | A1 |
20080195207 | Lin et al. | Aug 2008 | A1 |
20080208341 | McCormack et al. | Aug 2008 | A1 |
20080215151 | Kohm et al. | Sep 2008 | A1 |
20080228135 | Snoderly | Sep 2008 | A1 |
20080243249 | Kohm et al. | Oct 2008 | A1 |
20080249604 | Donovan et al. | Oct 2008 | A1 |
20080269761 | Truckai et al. | Oct 2008 | A1 |
20080269795 | Reiley et al. | Oct 2008 | A1 |
20080269796 | Reiley et al. | Oct 2008 | A1 |
20080300687 | Lin et al. | Dec 2008 | A1 |
20090030399 | Raiszadeh | Jan 2009 | A1 |
20090054990 | Myint et al. | Feb 2009 | A1 |
20090069899 | Klein | Mar 2009 | A1 |
20090076518 | Bowman et al. | Mar 2009 | A1 |
20090076610 | Afzal | Mar 2009 | A1 |
20090112221 | Burke et al. | Apr 2009 | A1 |
20090112323 | Hestad et al. | Apr 2009 | A1 |
20090125031 | Melsheimer et al. | May 2009 | A1 |
20090156995 | Martin et al. | Jun 2009 | A1 |
20090182268 | Thielen et al. | Jul 2009 | A1 |
20090182386 | Schaller | Jul 2009 | A1 |
20090187249 | Osman | Jul 2009 | A1 |
20090204216 | Biedermann et al. | Aug 2009 | A1 |
20090222093 | Liu et al. | Sep 2009 | A1 |
20090222097 | Liu et al. | Sep 2009 | A1 |
20090234457 | Lotz et al. | Sep 2009 | A1 |
20090299476 | Diwan et al. | Dec 2009 | A1 |
20090312697 | Zemlock | Dec 2009 | A1 |
20100069734 | Worley et al. | Mar 2010 | A1 |
20100106155 | Anderson et al. | Apr 2010 | A1 |
20100137990 | Apatsidis et al. | Jun 2010 | A1 |
20100145454 | Hoffman | Jun 2010 | A1 |
20100168858 | Hardenbrook et al. | Jul 2010 | A1 |
20100168859 | Wardlaw | Jul 2010 | A1 |
20100174375 | Schaller | Jul 2010 | A1 |
20100185286 | Allard et al. | Jul 2010 | A1 |
20100204794 | Jarzem et al. | Aug 2010 | A1 |
20100222824 | Simonson | Sep 2010 | A1 |
20100228239 | Freed | Sep 2010 | A1 |
20100256646 | Pinal et al. | Oct 2010 | A1 |
20100256647 | Trieu | Oct 2010 | A1 |
20100262242 | Chavatte et al. | Oct 2010 | A1 |
20100305703 | Lin | Dec 2010 | A1 |
20100318189 | Edie et al. | Dec 2010 | A1 |
20110004308 | Marino et al. | Jan 2011 | A1 |
20110009971 | Johnson et al. | Jan 2011 | A1 |
20110066105 | Hart et al. | Mar 2011 | A1 |
Number | Date | Country | |
---|---|---|---|
20090105732 A1 | Apr 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11700509 | Jan 2007 | US |
Child | 12316789 | US | |
Parent | 11153776 | Jun 2005 | US |
Child | 11700509 | US | |
Parent | 11272299 | Nov 2005 | US |
Child | 11153776 | US | |
Parent | 11359335 | Feb 2006 | US |
Child | 11272299 | US |